Advice
Recommended for restricted use within NHS Scotland.
RECOMMENDATION
Irbesartan, for the treatment of renal disease in patients with hypertension and type 2 diabetes mellitus, is effective, but has not been shown to be any more effective than ACE inhibitors, which are generally less expensive products, and for which there is a strong evidence base in diabetic renal disease and other forms of cardiovascular disease.
Therefore, irbesartan should be considered, along with other angiotensin II antagonists licensed for diabetic renal disease, as an alternative in patients unable to tolerate an ACE inhibitor.
Download detailed advice21KB (PDF)
Medicine details
- Medicine name:
- Irbesartan (Aprovel®)
- SMC ID:
- 38/03
- Indication:
- Renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive drug regimen
- Pharmaceutical company
- Sanofi-Aventis
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 May 2003